Generate Biomedicines, Inc. (GENB)
| Market Cap | 1.52B |
| Revenue (ttm) | 31.89M +55.9% |
| Net Income | -249.52M |
| EPS | -4.98 |
| Shares Out | 127.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 390,143 |
| Open | 12.05 |
| Previous Close | 11.83 |
| Day's Range | 11.62 - 12.28 |
| 52-Week Range | 11.00 - 15.32 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 25.00 (+109.38%) |
| Earnings Date | May 3, 2026 |
About GENB
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for GENB stock is "Strong Buy." The 12-month stock price target is $25.0, which is an increase of 109.38% from the latest price.
News
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut
Flagship-backed Generate Biomedicines' shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious t...
Drug developer Generate Biomedicines raises $400 million in US IPO
Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each.
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
SOMERVILLE, Mass., Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and ...
Generate Biomedicines aims to raise $425 million in US IPO
Drug developer Generate Biomedicines said on Monday it was aiming to raise as much as $425 million in its initial public offering in the United States.
Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO
Generate Biomedicines filed for an initial public offering on Nasdaq under the symbol GENB.
Generate Biomedicines IPO Registration Document (S-1)
Generate Biomedicines has filed to go public with an IPO on the NASDAQ
Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up to $100 million in an initial public offeri...